First Interstate BancSystem (NASDAQ:FIBK – Get Free Report) had its price objective upped by analysts at Barclays from $36.00 to $38.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the financial services provider’s stock. Barclays‘s price objective would suggest a potential downside of 3.64% from the stock’s […]

Mastercraft Boat (NASDAQ:MCFT – Get Free Report) had its target price boosted by analysts at Truist Financial from $25.00 to $28.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial’s price objective points to a potential upside of 17.70% from the company’s current price. […]

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) had its price objective upped by research analysts at JPMorgan Chase & Co. from $115.00 to $125.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 0.84% from […]

T. Rowe Price Group (NASDAQ:TROW – Get Free Report) had its target price increased by research analysts at The Goldman Sachs Group from $90.00 to $92.00 in a report released on Tuesday,MarketScreener reports. The firm currently has a “sell” rating on the asset manager’s stock. The Goldman Sachs Group’s price objective points to a potential […]

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price objective lifted by Cantor Fitzgerald from $27.00 to $29.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 203.66% from the company’s previous close. […]

Tenable (NASDAQ:TENB – Get Free Report) had its price objective upped by stock analysts at JPMorgan Chase & Co. from $35.00 to $40.00 in a research note issued on Tuesday. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 19.51% from the […]

Icon (NASDAQ:ICLR – Get Free Report) had its target price upped by research analysts at Mizuho from $180.00 to $190.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Mizuho’s price objective points to a potential upside of 18.04% from the company’s previous […]

Micron Technology (NASDAQ:MU – Get Free Report) had its price target hoisted by investment analysts at Mizuho from $1,150.00 to $1,375.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the semiconductor manufacturer’s stock. Mizuho’s price objective points to a potential upside of 13.31% from the company’s […]

Value and Indexed Property Income (LON:VIP – Get Free Report) had its price target boosted by equities researchers at Berenberg Bank from GBX 199 to GBX 207 in a research note issued on Thursday,Digital Look reports. The brokerage currently has a “hold” rating on the stock. Berenberg Bank’s price objective would suggest a potential downside […]

Icon (NASDAQ:ICLR – Get Free Report) had its price objective lifted by investment analysts at Barclays from $150.00 to $160.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the medical research company’s stock. Barclays‘s price target would indicate a potential upside of 0.05% from the […]

CSX (NASDAQ:CSX – Get Free Report) had its price objective upped by research analysts at Royal Bank Of Canada from $47.00 to $51.00 in a note issued to investors on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the transportation company’s stock. Royal Bank Of Canada’s price target points to a potential upside […]

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its target price hoisted by stock analysts at Mizuho from $100.00 to $118.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price objective points to a potential upside of 47.48% from […]